5326372025-04-012025-06-305326372025-04-012025-06-30in-capmkt:OtherExpenses1Member5326372025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326372025-04-012025-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532637MANGALAMNOTLISTEDINE584F01014MANGALAM DRUGS AND ORGANICS LIMITEDMain BoardEquity2025-04-012026-03-312025-08-072025-07-30INRLakhsQuarterlyFirst quarterSingle segmentManufacturing of Bulk Drugs2025-08-0716:00:002025-08-0719:30:00Declaration of unmodified opinionfalsefalseNot Applicable2025-04-012025-06-30UnauditedStandalone57348700040005734910002333370000162453000931250004044500043809000129602000702771000-1292800000-1292800000800000080000000-1372800000000-137280000-1142000-138422000158282480000010-8.67-8.6700-8.67-8.67 1. The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. <BR> <BR> 2. The above un-audited Standalone financial results of the Company for the Quarter ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drug and Organics Limited) at their meeting held on August 07, 2025. <BR> <BR> 3. The Company's business activity falls within a single reportable Business Segment Viz. “Manufacturing of Bulk Drugs”. <BR> <BR> 4. The figures for the quarter ended 31st March 2025 are the balancing figures between the audited figures in respect of full financial year upto March 31 2025 and the unaudited published year- to- date figures upto December 31 2024 being the date of end of the third quarter of the financial year respectively whichever subjected to limited review. <BR> <BR> 5. .The Board of Directors of the Company at its meeting held on March 15 2024 and which has been further modified on June 18, 2024 considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited (First Transferor Company) and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) (Second Transferor Company) with Mangalam Drugs and Organics Limited (Transferee Company) and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to approval of Hon’ble National Company Law Tribunal. Tribunal has convened meeting for the creditors and shareholders has been scheduled for held on 12th August 2025. <BR> <BR> 6.Other Expenses <BR> Rs. in Lakhs <BR> Sr.No. Particulars Quarter Ended Year Ended <BR> 30.06.2025 31.03.2025 30.06.2024 31.03.2025 <BR> 1 Power & Fuel Expenses 446.30 662.75 610.83 2788.18 <BR> 2 Pollution Control Expenses 168.30 269.30 223.03 901.14 <BR> <BR> 7.The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation <BR> <BR> Other Expenses129602000Other comprehensive income [Abstract]-1142000-114200000-1142000UnauditedfalseV . S. SOMANI and CO.true2027-07-31